Isavuconazole
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Invasive Fungal Disease
Conditions
Invasive Fungal Disease
Trial Timeline
Feb 7, 2023 → Apr 11, 2025
NCT ID
NCT05630976About Isavuconazole
Isavuconazole is a approved stage product being developed by Pfizer for Invasive Fungal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05630976. Target conditions include Invasive Fungal Disease.
What happened to similar drugs?
4 of 20 similar drugs in Invasive Fungal Disease were approved
Approved (4) Terminated (2) Active (15)
🔄Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05630976 | Approved | Completed |
| NCT04550936 | Pre-clinical | Completed |
Competing Products
20 competing products in Invasive Fungal Disease